Recent Headlines
Within Generic Drugs
CEAT Sells 7 Acres Land in Bhandup for Rs. 130 Crores
CEAT Ltd, the flagship company of the 13,500 crore RPG Group and one of India’s leading tyre manufacturers has today signed an agreement with M/s. Ashford InfoTech Limited for development of a vacant portion of about 7 acres of land located at Village Road in Bhandup, Mumbai. The proceeds of... - March 12, 2008 - RPG
Xcelience Expands Its Early Drug Development Capabilities
The Tampa-based CRO is first to acquire next generation Xcelodose. - January 26, 2008 - Xcelience, LLC
Samaritan Pharma Strategically Advances Its Promising Alzheimer's Drug
Enters Service Agreement with Advinus Therapeutics, India to Validate Potential Memory Restoring Benefits of Alzheimer's Drug Caprospinol. Strategy is to Bolster Caprospinol Alzheimer's Data Package to Out-License to Big Pharma and Expand IND Application to Enter Human Trials. Samaritan... - January 09, 2008 - Samaritan Pharmaceuticals
Samaritan Announces the Granting of European Patent for New Type of Cardiovascular Plaque Clearing Drug SP-1000
Samaritan Pharmaceuticals has received a notice that a European Patent has been granted to Samaritan's SP-1000 (Cholesterol Recognition Sequence) drug for the treatment of cardiovascular disease. - January 09, 2008 - Samaritan Pharmaceuticals
Three Rivers Adds Territory of Ireland to Samaritan's Existing Exclusive Licensing Agreement to Market Amphocil in Greece and Cyprus
Samaritan has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece. - January 09, 2008 - Samaritan Pharmaceuticals
Samaritan Pharmaceuticals Welcomes Two New Independent Directors to Its Board
Samaritan has appointed two new independent members, Jack L. Ayala and Robert W. Crane, to its Board of Directors. Mr. Ayala and Mr. Crane bring valuable experience and their appointment strengthens Samaritan's commitment to maintain a majority of independent members that reflects today's best practices on its Board. Samaritan's board is now comprised of eight independent directors and two internal directors. - January 09, 2008 - Samaritan Pharmaceuticals
FDA Accepts Samaritan's Cushing's SP-6300 IND and Clears Phase II Study
The U.S. Food and Drug Administration (FDA) has completed its regulatory review of Samaritan's IND (Investigational New Drug) application for Cushing's syndrome SP-6300 and declared it has not identified any deficiencies in its IND filing. Accordingly, Samaritan can proceed with its proposed Phase II clinical study of Cushing's syndrome SP-6300's efficacy in patients experiencing Hypercortisolism. - January 04, 2008 - Samaritan Pharmaceuticals
Samaritan Expands Revenue Opportunities with Marketing Authorization Approval for HIV Drug Amphocil in Cyprus
Samaritan Pharmaceuticals, Inc. is pleased to announce that its subsidiary Samaritan Pharmaceuticals Europe, S.A. has received notification, from the Cyprus Ministry of Health, that its marketing authorization for HIV fungus drug Amphocil has been approved in Cyprus. The Cyprus Ministry of Health... - January 03, 2008 - Samaritan Pharmaceuticals
Actors Studio's Anna Strasberg Joins Samaritan Advisory Board of Directors
Ms. Anna Strasberg has joined Samaritan's Advisory Board. Anna Strasberg is best known for continuing the Actors Studio, where the work of her husband Lee Strasberg nurtured the talents of celebrities like Marlon Brando, Robert De Niro, Harvey Keitel, Paul Newman and Al Pacino. - January 03, 2008 - Samaritan Pharmaceuticals
Three Rivers Adds Territory of Ireland to Samaritan's Existing Exclusive Licensing Agreement to Market Amphocil in Greece and Cyprus
Samaritan Pharmaceuticals has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece. - January 03, 2008 - Samaritan Pharmaceuticals
EUSA Pharma Signs Exclusive Distribution Agreement with Samaritan for Anesthetic Pain Patch to Launch and Sell in Greece and Cyprus
Samaritan Pharmaceuticals, Inc. has signed an exclusive distribution agreement with EUSA Pharma to launch, promote, sell and support pain patch Rapydan in Greece and Cyprus. - January 03, 2008 - Samaritan Pharmaceuticals
‘Harsh Goenka Takes a Keen Note of Suchitra Krishnamurty’s Arty Comments’
The annual art camp by the RPG Academy of Art concluded with a warm brunch at the Marve beach house today. Pristine white was the theme of the locale and the breezy touch of sea winds along with the live band playing some groovy numbers got the enchantment heightened. After the week-long camp, the... - December 30, 2007 - RPG
KEC International Bags Two New Projects Worth Rs. 637 Crores
•Rs. 391 Crores win in Abu Dhabi; Largest single win ever, in dollar value terms, for KEC •Rs. 246 crores turnkey contract in Algeria - December 01, 2007 - RPG
KEC International Bags Two New Projects Worth Rs. 400 Crores
•Rs. 260 Crores Turnkey contract in Saudi Arabia •Rs. 140 Crores Turnkey contract in Namibia - December 01, 2007 - RPG
Samaritan Presented Favorable Caprospinol Data at Alzheimer's Drug Development Summit
In an in vivo 'Proof of Concept' study, Samaritan Pharmaceuticals, Inc. has confirmed Caprospinol's (SP-233) efficacy in its ability to dramatically decrease beta amyloid plaque in the brain, accompanied by a complete recovery of memory back to baseline (p=0.002), as shown in a Morris water maze task. This study confirms previously reported in vitro data and suggests Caprospinol may not only slow the progress of Alzheimer's, but may also reverse plaque-related brain injuries associated with AD. - November 27, 2007 - Samaritan Pharmaceuticals
Xcelience’s Scientific Director Selected to Lead Key Sessions on Upcoming Conferences
Dr. Steve Bannister’s expertise requested for several speaking engagements over the next year - October 31, 2007 - Xcelience, LLC
INVEGA™ Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL® in Acutely Ill Hospitalized Patients
In a comparison study between schizophrenia treatments INVEGA™ (paliperidone) Extended-Release Tablets and SEROQUEL® (quetiapine), Invega patients saw schizophrenia symptom improvements as early as five days into therapy and continued through the end of the two-week study period. Results were presented today at the 20th Annual U.S. Psychiatric and Mental Health Congress in Orlando, Florida. - October 13, 2007 - Johnson & Johnson
World-Renowned Physician and HIV Researcher Joins Samaritan's Advisory Board
Samaritan announced today the appointment of James E.K. Hildreth, M.D., a world renowned physician and HIV researcher, to its Scientific Advisory Board. The work of Dr. Hildreth in HIV/AIDS dates back to 1986 and focuses on blocking HIV infection by learning how HIV gets into cells. He has published more than 80 scientific articles and holds six patents. - October 03, 2007 - Samaritan Pharmaceuticals
Samaritan Licenses Tumor Inhibiting Cancer Drugs That Also Distinguish Cancerous Tumors to Improve on Chemotherapy
Samaritan announced that it has entered into an exclusive licensing agreement with Georgetown University for a patent covering the Peripheral Benzodiazepine Receptor (PBR) which has led to Cancer drug candidates with the ability to inhibit cancerous tumors; and an imaging technique that could possibly distinguish cancerous tumors for a more targeted and improved chemotherapy. - August 21, 2007 - Samaritan Pharmaceuticals
Samaritan Licenses Method to Identify Novel Anti-Tumor Drugs to Increase Cancer Compounds in Pipeline
Samaritan Pharmaceuticals has exclusively licensed a patent application entitled "Structure Based Drug Design of Steroid Inhibitors" from Georgetown University. - August 16, 2007 - Samaritan Pharmaceuticals
Xcelience Expanding Operations
The Tampa-based contract research organization acquires a brand new building. - July 23, 2007 - Xcelience, LLC
Xcelience Will Acquire New Technologies to Enhance Drug Development Processes
The Tampa-based Contract Research Organization signed a partnership that will form new opportunities in the pharmaceutical industry. - May 24, 2007 - Xcelience, LLC
Xcelience Employs "CFS1200 Capsule Filling and Sealing Machine"
Xcelience's implementation of the CFS1200 will allow its formulation scientists the opportunity to accelerate the drug development timeframe. - March 13, 2007 - Xcelience, LLC
Xcelience Completes Successful QP Audit of Production Facility for European Market
Xcelience achives its third successful audit. - March 09, 2007 - Xcelience, LLC
Xcelience Debuts its Innovative and Interactive Forum: XpertXchange™
XpertXchange will initiate dialogue between Xcelience scientists and drug development professionals. - March 02, 2007 - Xcelience, LLC
Xcelience Launches Drug Development Consulting Service
The launch of Xpert Consulting will provide supplemental services to assist clients. - January 17, 2007 - Xcelience, LLC
Diluted Insulin Injections for Type 1 Diabetes Sufferers Are Now Available at Teregen Labs
Pharmacists at Teregen Labs can prepare diluted insulin in response to the growing need not met through retail pharmacies. When a Diluted Insulin Injection is needed, often when a patient is on an insulin pump, things typically get worse for diabetes sufferers. Teregen Labs regularly dilutes Insulin for diabetes sufferers with a valid prescription from their physician faxed into their pharmacy for an affordable price. - January 16, 2007 - Teregen Labs
Hovione Expands its Range of Services in Particle Design Technology
Hovione has increased its range of services and multi-scale facilities in cGMP Spray Drying, an advanced particle design technology. Building on its accumulated expertise in all major areas of API development and cGMP manufacture, a full range of cGMP Spray Drying facilities operating at lab, pilot and industrial scale have now been installed at Hovione's API manufacturing plant in Europe and are currently being installed at Hovione’s Technology Transfer Centre in New Jersey, USA. - August 26, 2005 - Hovione